Preliminary Study on Hepatoprotective Activity of Aqueous Crude Extract of Allium ascalonicum against Ethanol-induced Liver Injury in Mice

Sakaewan  OUNJAIJEAN; Voravuth  SOMSAK

doi:10.48048/wjst.2020.10708

Authors

Sakaewan OUNJAIJEAN School of Health Science Research, Research Institute for Health Sciences, Chiang Mai University, Chiang Mai 50200, Thailand
Voravuth SOMSAK School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80161, Thailand

DOI:

https://doi.org/10.48048/wjst.2020.10708

Keywords:

Hepatoprotective, Allium ascalonicum, Ethanol-induced liver injury

Abstract

Ethanol-induced liver injury is an aggravated liver disease with a diverse spectrum from steatosis to hepatitis, fibrosis, and cirrhosis. Epidemiological studies reveal that ethanol-induced liver injury has become one of the most intense threats to global health. Therefore, this study investigated the hepatoprotective property of Allium ascalonicum extract against ethanol-induced liver injury in mice. Aqueous crude extract of A. ascalonicum bulbs was prepared, and acute toxicity was, then, carried out in mice. The results indicated that A. ascalonicum extract at the dose up to 2,000 mg/kg/day did not cause mortality and liver injury as indicated by non-significant differences in AST, ALT, GGT, and ALP levels, compared to healthy control within the monitoring period. For in vivo efficacy test, the experimental mice were orally administered with 50 % (v/v) ethanol for 14 consecutive days, then further treated with the extract (50, 100, and 200 mg/kg) once a day for another 7 consecutive days. Significant, dose-dependent decrease of AST, ALT, GGT, and ALP levels was observed in ethanol-induced liver injury mice treated with A. ascalonicum extract. The present study clearly demonstrated that the aqueous crude extract of A. ascalonicum bulbs exert a hepatoprotective effect against ethanol-induced liver injury in the mice model. A. ascalonicum extract might be a promising remedy to treat alcoholic liver disease.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

PD Axley, CT Richardson and AK Singal. Epidemiology of alcohol consumption and societal burden of alcoholism and alcoholic liver disease. Clin. Liver Dis. 2019; 23, 39-50.

M Thavorncharoensap, Y Teerawattananon, J Yothasamut, C Lertpitakpong, K Thitiboonsuwan, P Neramitpitagkul and U Chaikledkaew. The economic costs of alcohol consumption in Thailand, 2006. BMC Public Health 2010; 10, 323.

T Thamarangsi. Thailand: Alcohol today. Addiction 2006; 101, 783-7.

M Wakabayashi, R McKetin, C Banwell, V Yiengprugsawan, M Kelly, SA Seubsman, H Iso, A Sleigh and Thai Cohort Study Team. Alcohol consumption patterns in Thailand and their relationship with non-communicable disease. BMC Public Health 2015; 15, 1297.

E Albano. Alcohol, oxidative stress and free radical damage. Proc. Nutr. Soc. 2006; 65, 278-90.

CS Lieber. Alcoholic fatty liver: Its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol 2004; 34, 9-19.

S Li, HY Tan, N Wang, ZJ Zhang, L Lao, CW Wong and Y Feng. The role of oxidative stress and antioxidants in liver diseases. Int. J. Mol. Sci. 2015; 16, 26087-124.

E Ceni, T Mello and A Galli. Pathogenesis of alcoholic liver disease: Role of oxidative metabolism. World J. Gastroenterol. 2014; 20, 17756-72.

PK Eagon. Alcoholic liver injury: Influence of gender and hormones. World J. Gastroenterol. 2010; 16, 1377-84.

F Stickel, HK Seitz, EG Hahn and D Schuppan. Alcoholic liver disease-established treatment and new therapeutic approaches. Zeitschrift für Gastroenterol. 2003; 41, 333-42.

H Yao, YJ Qiao, YL Zhao, XF Tao, LN Xu, LH Yin, Y Qi and JY Peng. Herbal medicines and nonalcoholic fatty liver disease. World J. Gastroenterol. 2016; 22, 6890-905.

N Shang, A Saleem, L Musallam, B Walshe-Roussel, A Badawi, A Cuerrier, JT Arnason and PS Haddad. Novel approach to identify potential bioactive plant metabolites: Pharmacological and metabolomics analyses of ethanol and hot water extracts of several Canadian medicinal plants of the Cree of Eeyou Istchee. PloS One 2015; 10, e0135721.

RB Ding, K Tian, LL Huang, CW He, Y Jiang, YT Wang and JB Wan. Herbal medicines for the prevention of alcoholic liver disease: A review. J. Ethnopharmacol. 2012; 144, 457-65.

J Sharifi-Rad, D Mnayer, G Tabanelli, ZZ Stojanovic-Radic, M Sharifi-Rad, Z Yousaf, L Vallone, WN Setzer and M Iriti. Plants of the genus Allium as antibacterial agents: From tradition to pharmacy. Cell. Mol. Biol. 2016; 62:57-68.

HR Mohammadi-Motlagh, A Mostafaie and K Mansouri. Anticancer and anti-inflammatory activities of shallot (Allium ascalonicum) extract. Arch. Med. Sci. 2011; 7, 38-44.

S Saenthaweesuk, R Jitvaropas, N Somparn and A Thuppia. An investigation of antimicrobial and wound healing potential of Allium ascalonicum Linn. J. Med. Assoc. Thai. 2015; 98, S22-7.

D Mnayer, AS Fabiano-Tixier, E Petitcolas, T Hamieh, N Nehme, C Ferrant, X Fernandez and F Chemat. Chemical composition, antibacterial and antioxidant activities of six essentials oils from the Alliaceae family. Molecules 2014; 19, 20034-53.

MF Sani, SM Kouhsari and L Moradabadi. Effects of three medicinal plants extracts in experimental diabetes: Antioxidant enzymes activities and plasma lipids profiles in comparison with metformin. Iran J. Pharm. Res. 2012; 11, 897-903.

O Wongmekiat, N Leelarugrayub and K Thamprasert. Beneficial effect of shallot (Allium ascalonicum L.) extract on cyclosporine nephrotoxicity in rats. Food Chem. Toxicol. 2008; 46, 1844-50.

E Fattorusso, M Iorizzi, V Lanzotti and O Taglialatela-Scafati. Chemical composition of shallot (Allium ascalonicum Hort.). J. Agric. Food Chem. 2002; 50, 5686-90.

MJ Guan, N Zhao, KQ Xie and T Zeng. Hepatoprotective effects of garlic against ethanol-induced liver injury: A mini-review. Food Chem. Toxicol. 2018; 111, 467-73.

D Lorke. A new approach to practical acute toxicity testing. Arch. Toxicol. 1983; 54, 275-87.

EM Smith. The organisation for economic cooperation and development (OECD) and chemical safety. IARC Sci. Publ. 1980; 27, 361-4.

TM Leung and Y Lu. Alcoholic liver disease: From CYP2E1 to CYP2A5. Curr. Mol. Pharmacol. 2017; 10, 172-8.

KH Han, N Hashimoto and M Fukushima. Relationships among alcoholic liver disease, antioxidants, and antioxidant enzymes. World J. Gastroenterol. 2016; 22, 37-49.

BA Potz, IJ Lawandy, RT Clements and FW Sellke. Alcohol modulates autophagy and apoptosis in pig liver tissue. J. Surg. Res. 2016; 203, 154-62.

B Relja, R Weber, M Maraslioglu, N Wagner, T Borsello, C Jobin, I Marzi and M Lehnert. Differential relevance of NF-kappaB and JNK in the pathophysiology of hemorrhage/resususcitation-induced liver injury after chronic ethanol feeding. PloS One 2015; 10, e0137875.

M Maraslioglu, R Weber, S Korff, C Blattner, C Nauck, D Henrich, C Jobin, I Marzi and M Lehnert. Activation of NF-kappaB after chronic ethanol intake and haemorrhagic shock/resuscitation in mice. Br. J. Pharmacol. 2013; 170, 506-18.

SK Bedada and P Neerati. The effect of quercetin on the pharmacokinetics of chlorzoxazone, a CYP2E1 substrate, in healthy subjects. Eur. J. Clin. Pharmacol. 2018; 74, 91-7.

X Chen. Protective effects of quercetin on liver injury induced by ethanol. Pharmacogn. Mag. 2010; 6, 135-41.

A Vidhya and M Indira. Protective effect of quercetin in the regression of ethanol-induced hepatotoxicity. Indian J. Pharm. Sci. 2009; 71, 527-32.

J Ostlund, V Zlabek and G Zamaratskaia. In vitro inhibition of human CYP2E1 and CYP3A by quercetin and myricetin in hepatic microsomes is not gender dependent. Toxicology 2017; 381, 10-8.

Y Tang, H Tian, Y Shi, C Gao, M Xing, W Yang, W Bao, D Wang, L Liu and P Yao. Quercetin suppressed CYP2E1-dependent ethanol hepatotoxicity via depleting heme pool and releasing CO. Phytomedicine 2013; 20, 699-704.

H Wang, R Peng, R Kong and H Zeng. Effect of allicin on ethanol-induced hepatotoxicity in mice. J. Hyg. Res. 1998; 27, 415-7.